Navigation Links
China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
Date:8/8/2008

HARBIN, China, Aug. 8 /Xinhua-PRNewswire-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Amex: CSY), a manufacturer, marketer and distributor of pharmaceutical, medicinal and diagnostic products in China, today announced that it will conduct a conference call at 10:00 a.m. Eastern Time on August 12, 2008 to discuss its second quarter 2008 financial results.

Joining Mr. Yan-qing Liu, Chairman, CEO and Director of China Sky One Medical, Inc., will be Yu-bo Hao, Board Secretary. The Company plans to issue an earnings announcement prior to the call.

To participate in the live conference call, please dial the following number five to ten minutes prior to the scheduled conference call time: 866-573-1052. International callers should dial 702-696-4500. The Conference ID for this call is 59672695.

If you are unable to participate in the call at this time, a replay will be available for fourteen days starting on Tuesday, August 12, 2008 at 12 p.m. Eastern Time. To access the replay, dial 800-642-1687, international callers dial 706-645-9291 Conference ID 59672695.

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company whose principal operations are through its subsidiaries, which are engaged in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic kit products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR") and Harbin First Bio-Engineering Company Limited ("First"), the Company manufactures and distributes over-the-counter pharmaceutical products as its primary revenue source. For more information, visit http://www.skyonemedical.com .

Safe Harbor Statement

Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding our future plans, objectives or performance. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

For more information, please contact:

Company Contact:

China Sky One Medical, Inc.

Mr. Yubo Hao, Board Secretary

Tel: +86-451-5399-4069

Email: china_sky_one@yahoo.cn

Investor Relations Contact:

CCG Investor Relations

Mr. Crocker Coulson, President

Tel: +1-646-213-1915

Email: crocker.coulson@ccgir.com

Mr. Richard Micchelli, Financial Writer

Tel: +1-646-454-4516

Email: richard.micchelli@ccgir.com

Web: http://www.ccgir.com


'/>"/>
SOURCE China Sky One Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
2. China Nepstar Chain Drugstore to Announce Second Quarter 2008 Financial Results on August 27
3. China Pharma Holdings, Inc. Announces Second Quarter 2008 Financial Results
4. China Biologic Products Begins Annual Maintenance of its Production Facilities
5. China Pharma Holdings, Inc. to Host Second Quarter 2008 Earnings Conference Call at 10 a.m. EDT Wednesday August 6, 2008
6. China Biologic Products Establishes Audit Committee and Appoints Three New Independent Directors to Board of Directors
7. Global Stem Cell Forum in China Showcases Cutting Edge Research, Focuses on New Findings for iPS Cells
8. China Medical Technologies Adjusts Conversion Rate of Convertible Notes
9. China-Biotics, Inc. Files Application for Nasdaq Listing
10. China Biologic Products Honored with the Advanced Technology Certification for Foreign-Funded Enterprises
11. China-Biotics, Inc. Announces Appointment of New Transfer Agent Effective August 15, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... , ... June 22, 2017 , ... ... leaders in designating infertility as a disease, bringing new hope for prospective parents ... their 2017 annual meeting to back the World Health Organization’s designation in hopes ...
(Date:6/22/2017)... ... June 22, 2017 , ... Tunnell ... the biopharma and life sciences industries, continue to be in demand for their ... Wolf will be speaking on “The State of Information Governance in the Biopharmaceutical ...
(Date:6/22/2017)... ... June 22, 2017 , ... RURO, Inc., ... Limfinity® version 6.5, a content-packed update to the Limfinity® framework. , LimitLIS® and ... and more diverse base of customers among labs and other businesses. Limfinity® 6.5 ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... CTNext board of directors has formed a Higher Education Entrepreneurship Advisory Committee to ... of institution presidents and other high-ranking representatives from 35 higher education institutions across ...
Breaking Biology Technology:
(Date:4/13/2017)... 13, 2017 According to a new market research ... Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and ... is expected to grow from USD 14.30 Billion in 2017 to USD ... 17.3%. ... MarketsandMarkets Logo ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
Breaking Biology News(10 mins):